# EDGAR Filing Document

**Accession Number:** 0001744099
**File Stem:** 0001178913-23-000242
**Filing Date:** 2023-1
**Character Count:** 9068
**Document Hash:** b715b94ae389b25852f5b2d0d7b2bbe2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-23-000242.hdr.sgml**: 20230124

**ACCESSION NUMBER**: 0001178913-23-000242

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230119

**FILED AS OF DATE**: 20230124

**DATE AS OF CHANGE**: 20230124

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** aMoon Growth Fund Limited Partnership
- **CENTRAL INDEX KEY:** 0001744099
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39279
- **FILM NUMBER:** 23546232

**BUSINESS ADDRESS:**
- **STREET 1:** 34 YERUSHALAYIM RD.
- **CITY:** RAANANA
- **STATE:** L3
- **ZIP:** 4350110
- **BUSINESS PHONE:** 972(73)3989560

**MAIL ADDRESS:**
- **STREET 1:** 34 YERUSHALAYIM RD.
- **CITY:** RAANANA
- **STATE:** L3
- **ZIP:** 4350110

**FORMER NAME:**
- **FORMER CONFORMED NAME:** aMoon 2 Fund Limited Partnership
- **DATE OF NAME CHANGE:** 20180620
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Schindel Yair Chaim
- **CENTRAL INDEX KEY:** 0001823758

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39279
- **FILM NUMBER:** 23546231

**MAIL ADDRESS:**
- **STREET 1:** YERUSHALAYIM ROAD 34
- **STREET 2:** BEIT GAMLA ENTRANCE B
- **CITY:** RA'ANANA
- **STATE:** L3
- **ZIP:** 4350110
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Old Ayala, Inc
- **CENTRAL INDEX KEY:** 0001797336
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 823578375
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1313 N. MARKET STREET
- **STREET 2:** SUITE 5100
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801
- **BUSINESS PHONE:** (857) 444-0553

**MAIL ADDRESS:**
- **STREET 1:** 1313 N. MARKET STREET
- **STREET 2:** SUITE 5100
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ayala Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20191218

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>aMoon Growth Fund Limited Partnership<br><sub>(Last) (First) (Middle)</sub><br>34 YERUSHALAIM ROAD<br>BEIT GAMLA, 6TH FLOOR<br><sub>(Street)</sub><br>RAANANA, L3 4350110<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-01-19 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Old Ayala, Inc [ AYLA ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Schindel Yair Chaim<br><sub>(Last) (First) (Middle)</sub><br>34 YERUSHALAIM ROAD<br>BEIT GAMLA, 6TH FLOOR<br><sub>(Street)</sub><br>RAANANA, L3 4350110<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-01-19 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[ ] Officer (give title below) [X] Other (specify below)<br>_shareholder of 10% holder_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Old Ayala, Inc [ AYLA ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-01-19 |  | D |  | 2991473 | D | <sup>(1)</sup> | 0 | D<sup>(2)</sup> |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, upon the consummation of the merger on January 19, 2023, each share of Ayala's common stock was cancelled and converted into the right to receive shares of Advaxis common stock based on the exchange ratio set forth therein.

(2) The reported shares were held of record by aMoon Growth Fund Limited Partnership ("aMoon Growth Fund"). aMoon Growth Fund G.P. Limited Partnership ("aMoon Growth Fund G.P.") is the sole General Partner of aMoon Growth Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon Growth Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may have been deemed to have shared voting and investment power with respect to the shares held of record by aMoon Growth Fund. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Growth Fund except to the extent of its or his pecuniary interest therein, if any.

**Signature:** /s/ Yair Schindel, the sole shareholder of aMoon General Partner Ltd., the sole General Partner of aMoon Growth Fund G.P. Limited Partnership, the sole General Partner of aMoon Growth Fund, Limited Partnership  
**Date:** 2023-01-24

**Signature:** /s/ Yair Schindel  
**Date:** 2023-01-24

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**